Last reviewed 2026-04-20 · How we verify

CARBIDOPA ANHYDROUS

FDA-approved approved Small molecule Quality 2/100

CARBIDOPA ANHYDROUS is a drug. It is currently FDA-approved (first approved 1975).

At a glance

Generic name	CARBIDOPA ANHYDROUS
Modality	Small molecule
Phase	FDA-approved
First approval	1975

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CARBIDOPA ANHYDROUS CI brief — competitive landscape report
CARBIDOPA ANHYDROUS updates RSS · CI watch RSS

Frequently asked questions about CARBIDOPA ANHYDROUS

What is CARBIDOPA ANHYDROUS?

CARBIDOPA ANHYDROUS is a Small molecule drug.

When was CARBIDOPA ANHYDROUS approved?

CARBIDOPA ANHYDROUS was first approved on 1975.

What development phase is CARBIDOPA ANHYDROUS in?

CARBIDOPA ANHYDROUS is FDA-approved (marketed).

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing